B+
Bull case
25%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
RNA
Atrium TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-25
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+71.6
Score
AI commentary
Primary-source operating evidence is constructive, but independent company-specific news is thin. No reliable analyst revisions, attributed post-release price reaction, or sufficiently covered social sentiment were supplied; the zero sentiment fields denote unavailable measurements, not neutral observations. September Form 4 dispositions were coded as tax withholding, not identified as discretionary open-market sales [#SEC-FORM4-2026-09-22].
RankAlpha Sentiment Codex - 2026-09-25
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventFirst participant in CorventisHigh impact
Atrium expects to enroll the first participant in its approximately 37-person Phase 1/2 ATR 1072 trial by year-end 2026. Timely enrollment would demonstrate execution after IND clearance, not clinical efficacy [#8-K-2026-08-13] [#SEC-8K-2026-08-13].
2027-12-31catalystInitial ATR 1072 proof-of-concept dataHigh impact
Atrium expects initial Corventis data in the second half of 2027. This is the principal clinical value inflection, but efficacy is unproven and the small, open-label study may be difficult to interpret [#SEC-8K-2026-08-13].
2027-12-31catalystATR 1086 IND filingHigh impact
Atrium plans IND-enabling studies in 2026 and an ATR 1086 IND filing in 2027. Progress could broaden the pipeline, though this program remains preclinical [#SEC-8K-2026-08-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-25 • Updated nightlySource: Internal modelMethodology